AAAAAA

   
Results: 1-13 |
Results: 13

Authors: Cleeman, JI Grundy, SM Becker, D Clark, LT Cooper, RS Denke, MA Howard, WJ Hunninghake, DB Illingworth, DR Luepker, RV McBride, P McKenney, JM Pasternak, RC Stone, NJ Van Horn, L Brewer, HB Ernst, ND Gordon, D Levy, D Rifkind, B Rossouw, JE Savage, P Haffner, SM Orloff, DG Proschan, MA Schwartz, JS Sempos, CT Shero, ST Murray, EZ
Citation: Ji. Cleeman et al., Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III), J AM MED A, 285(19), 2001, pp. 2486-2497

Authors: Illingworth, DR Tobert, JA
Citation: Dr. Illingworth et Ja. Tobert, HMG-CoA reductase inhibitors, ADV PROTEIN, 56, 2001, pp. 77-114

Authors: Jenkins, DJA Kendall, CWC Popovich, DG Vidgen, E Mehling, CC Vuksan, V Ransom, TPP Rao, AV Rosenberg-Zand, R Tariq, N Corey, P Jones, PJH Raeini, M Story, JA Furumoto, EJ Illingworth, DR Pappu, AS Connelly, PW
Citation: Dja. Jenkins et al., Effect of a very-high-fiber vegetable, fruit, and nut diet on serum lipidsand colonic function, METABOLISM, 50(4), 2001, pp. 494-503

Authors: Ginsberg, HN Illingworth, DR
Citation: Hn. Ginsberg et Dr. Illingworth, Postprandial dyslipidemia: An atherogenic disorder common in patients withdiabetes mellitus, AM J CARD, 88(6A), 2001, pp. 9H-15H

Authors: Durrington, PN Illingworth, DR
Citation: Pn. Durrington et Dr. Illingworth, Lipid-lowering drug therapy: more knowledge leads to more problems for composers of guidelines, CURR OP LIP, 11(4), 2000, pp. 345-349

Authors: Ohashi, K Ishibashi, S Osuga, J Tozawa, R Harada, K Yahagi, N Shionoiri, F Iizuka, Y Tamura, Y Nagai, R Illingworth, DR Gotoda, T Yamada, N
Citation: K. Ohashi et al., Novel mutations in the microsomal triglyceride transfer protein gene causing abetalipoproteinemia, J LIPID RES, 41(8), 2000, pp. 1199-1204

Authors: Raal, FJ Pappu, AS Illingworth, DR Pilcher, GJ Marais, AD Firth, JC Kotze, MJ Heinonen, TM Black, DM
Citation: Fj. Raal et al., Inhibition of cholesterol synthesis by atorvastatin in homozygous familialhypercholesterolaemia, ATHEROSCLER, 150(2), 2000, pp. 421-428

Authors: Illingworth, DR Durrington, PN
Citation: Dr. Illingworth et Pn. Durrington, Dyslipidemia and atherosclerosis: how much more evidence do we need?, CURR OP LIP, 10(5), 1999, pp. 383-386

Authors: O'Malley, JP Maslen, CL Illingworth, DR
Citation: Jp. O'Malley et al., Angiotensin-converting enzyme and cardiovascular disease risk, CURR OP LIP, 10(5), 1999, pp. 407-415

Authors: Stein, EA Illingworth, DR Kwiterovich, PO Liacouras, CA Siimes, MA Jacobson, MS Brewster, TG Hopkins, P Davidson, M Graham, K Arensman, F Knopp, RH DuJovne, C Williams, CL Isaacsohn, JL Jacobsen, CA Laskarzewski, PM Ames, S Gormley, GJ
Citation: Ea. Stein et al., Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia - A randomized controlled trial, J AM MED A, 281(2), 1999, pp. 137-144

Authors: Guyton, JR Dujovne, CA Illingworth, DR
Citation: Jr. Guyton et al., Dual hepatic metabolism of cerivastatin-clarifications, AM J CARD, 84(4), 1999, pp. 497-497

Authors: Maslen, CL Illingworth, DR
Citation: Cl. Maslen et Dr. Illingworth, Cholesteryl ester hydrolase deficiency, LIPOPROTEINS IN HEALTH AND DISEASE, 1999, pp. 847-861

Authors: Illingworth, DR
Citation: Dr. Illingworth, 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, LIPOPROTEINS IN HEALTH AND DISEASE, 1999, pp. 1161-1179
Risultati: 1-13 |